ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.76 +0.44 (+2.17%)

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Jim Cramer Believes In Dell CEO, Doesn't Like B&G Foods ↗

August 27, 2024

Cramer gives his take on E.l.f Beauty, Acadia Pharmaceuticals, B&G Foods, Lucid, SoFi, Dell, Johnson & Johnson, UWM and Symbotic.

Via Benzinga

Ryan Reynolds Announces More to Parkinson’s® Campaign

August 14, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

August 07, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' ↗

August 07, 2024

Acadia led a biotech selloff on Wednesday as Daybue sales missed expectations.

Via Investor's Business Daily

Topics Earnings

Expert Outlook: ACADIA Pharmaceuticals Through The Eyes Of 5 Analysts ↗

August 07, 2024

Via Benzinga

A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals ↗

July 12, 2024

Via Benzinga

Expert Ratings For ACADIA Pharmaceuticals ↗

June 25, 2024

Via Benzinga

Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

August 07, 2024

Via Benzinga

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

August 06, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

July 24, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

July 18, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Cracking The Code: Understanding Analyst Reviews For ACADIA Pharmaceuticals ↗

April 10, 2024

Via Benzinga

This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

June 27, 2024

Via Benzinga

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

June 18, 2024

From Acadia Pharmaceuticals, Inc.

Via Business Wire

3 Sorry Pharma Stocks to Sell in May While You Still Can ↗

May 29, 2024

Discover three pharma stocks to sell in May while you still can. Avoid these companies facing significant setbacks.

Via InvestorPlace

After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February ↗

May 24, 2024

Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.

Via Benzinga

Topics Data Breach

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 17, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome

May 15, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Shhh! 3 Secret Penny Stocks Flying Below Wall Street’s Radar ↗

May 09, 2024

Under-the-radar penny stocks can be some of the most rewarding investments on the market. Here are three to consider.

Via InvestorPlace

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

May 09, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACAD Stock Earnings: ACADIA Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ↗

May 08, 2024

ACAD stock results show that ACADIA Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview

May 08, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (25 Ratings) ↗

April 30, 2024

Via Benzinga

Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship

April 29, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024

April 24, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

April 22, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 19, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting

April 17, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

3 Pharma Stocks to Sell in April Before They Crash & Burn ↗

April 11, 2024

Discover three pharma stocks to sell in April, facing challenges and signaling potential for significant downside.

Via InvestorPlace

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

April 02, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.